San Jose, California (PRWEB) January 23, 2014
Follow us on LinkedIn – Hormone Replacement Therapy refers to use of hormones - estrogens and progestin for alleviating symptoms associated with menopause. HRT represents a highly challenging market for drug manufacturers, mainly due to safety issues surrounding usage of synthetic sources of estrogen. While safety concerns and legal challenges continue to threaten growth prospects in the global HRT market, manufacturers have been active in addressing some of the health concerns by developing ultra-low and low dose drug versions. Although not backed or supported by significant clinical data for validating their safety, the low-dose versions, when used for shorter periods, have been successful in addressing a part of the unmet needs and have buoyed the HRT market in recent years.
Growth in the HRT market is also constrained by increasing competition from generics, bioidentical hormones, custom compounded medications and competition from non-hormonal products. However, new product approvals and growth opportunities from emerging countries are expected to drive the market in the foreseeable future.
HRT products are available in various forms, such as oral tablets, vaginal tablets and rings, transdermal patches, syringes, sprays, vaginal cream, intrauterine systems as well as combination products. Oral formulations are giving way to topical formulations in estrogen therapy. Transdermal systems currently account for a nominal share in the US hormone replacement therapy market. However, their popularity and use is expected to increase in the coming years as physicians realize the higher safety aspects associated with these products when compared to oral formulations. Also, emergence of new products is expected to fuel transition towards transdermal products. Meanwhile, transdermal estrogen products are hugely popular in Europe, with the segment accounting for major share of the estrogen market.
As stated by the new market research report on Hormone Replacement Therapy, the United States represents the single largest market worldwide. Asia-Pacific represents the market with the highest growth potential. Growth in the region is being led by improving healthcare expenditure, rising life expectancies, and increase in the number of research studies focused on ascertaining the advantages of HRT for postmenopausal indications.
Key players covered in the report include Abbott Laboratories, AbbVie Inc., Actavis Plc, Bayer Pharma AG, Hisamitsu Pharmaceutical Co Inc., Noven Pharmaceuticals Inc., Novartis AG, Novo Nordisk A/S, Orion Corporation, Pfizer Inc., Rottapharm Madaus, Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories Inc., among others.
The research report titled "Hormone Replacement Therapy (HRT): A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the market, industry overview, trends, growth drivers, latest product launches and recent industry activity. The report provides market estimates and projections in US dollars for major geographic markets including the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World for the years 2012 through 2020. The report also offers historic market estimates and projections in US dollars for the years 2006 through 2011.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/